Genotype–phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran
- 20 December 2011
- journal article
- Published by Springer Nature in International Journal of Hematology
- Vol. 95 (1) , 51-56
Abstract
We evaluated the clinical responses to hydroxyurea (HU), adverse effects, and β-globin gene variants in a large series of β-thalassemic patients over a 13-year period in Iran. The patients (n = 232) were divided into two groups: transfusion-dependent β-thalassemia patients 2 years of age and older (n = 126; Group 1), and β-thalassemia intermedia (βTI) patients without any history of blood transfusion or with a long-interval transfusion (n = 106; Group 2). In Group 1, 86 patients became transfusion-free, and 25 patients needed 1–2 transfusions per year at the end of study. All except three patients in Group 2 were completely transfusion free with a significant increase in Hb level after 1 year compared to the baseline Hb value (P < 0.0001). We did not find a significant correlation of response to HU with XmnI polymorphism or IVS II-I (G > A) mutation (P > 0.05). In our study, HU at a dose of 8–15 mg/kg/day was effective in decreasing or effecting cessation of the need for regular blood transfusion, as well as in increasing Hb levels in β-thalassemia patients, without any major side effects. Hydroxyurea may thus represent a safe alternative to blood transfusion in transfusion-dependent β-thalassemia patients, or help to increase Hb level in untransfused βTI patients.Keywords
This publication has 28 references indexed in Scilit:
- ADVERSE EFFECTS OF HYDROXYUREA IN β-THALASSEMIA INTERMEDIA PATIENTS: 10 Years’ ExperiencePediatric Hematology and Oncology, 2010
- HYDROXYUREA-INDUCED HEMATOLOGICAL RESPONSE IN TRANSFUSION-INDEPENDENT BETA-THALASSEMIA INTERMEDIA: Case Series and Review of LiteraturePediatric Hematology and Oncology, 2009
- Response to hydroxyurea therapy in β‐thalassemiaAmerican Journal of Hematology, 2008
- Treatment of Thalassemia With Hydroxyurea: An Indispensable Alternative TherapyJournal of Pediatric Hematology/Oncology, 2007
- Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermediaTransfusion, 2007
- Hydroxyurea Use in Lebanese Patients With β-Thalassemia IntermediaJournal of Pediatric Hematology/Oncology, 2006
- Cutaneous Adverse Reactions to Hydroxyurea in Patients with Intermediate ThalassemiaPediatric Dermatology, 2004
- Hydroxyurea can eliminate transfusion requirements in children with severe β-thalassemiaBlood, 2003
- Hydroxyurea Therapy in ThalassemiaaAnnals of the New York Academy of Sciences, 1998
- Pharmacologic treatment of thalassemia intermedia with hydroxyureaThe Journal of Pediatrics, 1994